See more : DUET Acquisition Corp. (DUETU) Income Statement Analysis – Financial Results
Complete financial analysis of Novartis AG (NVS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Novartis AG, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
You may be interested
- Brikor Limited (BIK.JO) Income Statement Analysis – Financial Results
- Forsys Metals Corp. (FOSYF) Income Statement Analysis – Financial Results
- First Tellurium Corp. (FSTTF) Income Statement Analysis – Financial Results
- Harmony Biosciences Holdings, Inc. (HRMY) Income Statement Analysis – Financial Results
- Rothschild & Co SCA (ROTH.PA) Income Statement Analysis – Financial Results
Novartis AG (NVS)
About Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 46.66B | 51.83B | 52.88B | 49.90B | 48.68B | 53.17B | 50.14B | 49.44B | 50.39B | 53.63B | 58.83B | 57.56B | 59.38B | 51.56B | 45.10B | 42.58B | 38.95B | 36.75B | 32.53B | 28.25B | 24.86B | 23.15B | 19.34B | 21.83B | 20.42B | 23.04B |
| Cost of Revenue | 12.47B | 15.49B | 15.87B | 15.12B | 14.43B | 18.41B | 17.18B | 17.52B | 17.40B | 17.35B | 19.61B | 18.76B | 18.98B | 14.49B | 12.18B | 11.44B | 11.03B | 10.30B | 8.87B | 6.63B | 5.89B | 5.44B | 4.76B | 6.25B | 5.23B | 7.31B |
| Gross Profit | 34.19B | 36.34B | 37.01B | 34.78B | 34.25B | 34.76B | 32.96B | 31.92B | 32.98B | 36.29B | 39.22B | 38.81B | 40.39B | 37.07B | 32.92B | 31.15B | 27.92B | 26.45B | 23.66B | 21.62B | 18.97B | 17.71B | 14.58B | 15.59B | 15.19B | 15.73B |
| Gross Profit Ratio | 73.27% | 70.12% | 69.99% | 69.70% | 70.37% | 65.38% | 65.74% | 64.56% | 65.46% | 67.66% | 66.67% | 67.42% | 68.03% | 71.90% | 73.00% | 73.14% | 71.67% | 71.97% | 72.74% | 76.55% | 76.30% | 76.50% | 75.39% | 71.40% | 74.39% | 68.29% |
| Research & Development | 11.37B | 10.00B | 9.54B | 8.98B | 9.40B | 9.07B | 8.97B | 9.04B | 8.94B | 9.09B | 9.85B | 9.33B | 9.58B | 9.07B | 7.47B | 7.22B | 6.43B | 5.35B | 4.85B | 4.21B | 3.76B | 3.10B | 2.53B | 2.84B | 2.67B | 2.71B |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 16.47B | 2.14B | 2.19B | 2.48B | 2.62B | 3.06B | 2.94B | 2.97B | 2.48B | 2.28B | 2.25B | 2.13B | 1.96B | 1.74B | 1.54B | 0.00 | 8.98B | 7.66B | 7.94B | 6.95B | 1.29B |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.86B | 12.00B | 11.77B | 12.38B | 14.55B | 14.35B | 15.08B | 13.32B | 12.05B | 11.85B | 11.13B | 10.45B | 9.80B | 8.87B | 9.33B | 0.00 | 0.00 | 0.00 | 0.00 | 6.39B |
| SG&A | 12.49B | 14.25B | 14.89B | 14.20B | 14.37B | 16.47B | 15.00B | 14.19B | 14.25B | 14.99B | 17.61B | 17.29B | 18.05B | 15.80B | 14.33B | 14.10B | 13.26B | 12.41B | 11.54B | 10.41B | 9.33B | 8.98B | 7.66B | 7.94B | 6.95B | 7.68B |
| Other Expenses | 559.00M | 2.90B | 895.00M | 1.45B | 1.40B | 1.05B | 362.00M | 417.00M | 824.00M | 1.12B | 852.00M | 672.00M | 1.76B | 680.00M | 1.14B | 867.00M | 1.45B | 741.00M | 363.00M | 463.00M | 0.00 | 0.00 | 0.00 | 0.00 | 949.00M | 0.00 |
| Operating Expenses | 24.42B | 27.15B | 25.32B | 24.63B | 25.17B | 26.59B | 24.33B | 23.65B | 24.01B | 25.20B | 28.31B | 27.29B | 29.39B | 25.55B | 22.94B | 22.18B | 21.13B | 18.50B | 16.75B | 15.08B | 13.08B | 12.08B | 10.18B | 10.78B | 10.57B | 10.39B |
| Cost & Expenses | 36.89B | 42.63B | 41.19B | 39.75B | 39.59B | 45.00B | 41.51B | 41.17B | 41.41B | 42.55B | 47.92B | 46.05B | 48.38B | 40.04B | 35.12B | 33.62B | 32.17B | 28.80B | 25.62B | 21.71B | 18.98B | 17.52B | 14.94B | 17.03B | 15.80B | 17.69B |
| Interest Income | 627.00M | 379.00M | 71.00M | 91.00M | 245.00M | 294.00M | 110.00M | 43.00M | 33.00M | 33.00M | 34.00M | 50.00M | 62.00M | 103.00M | 156.00M | 306.00M | 423.00M | 367.00M | 405.00M | 388.00M | 323.00M | 416.00M | 293.00M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 855.00M | 837.00M | 811.00M | 869.00M | 850.00M | 957.00M | 777.00M | 707.00M | 655.00M | 704.00M | 683.00M | 724.00M | 751.00M | 692.00M | 551.00M | 290.00M | 237.00M | 266.00M | 294.00M | 261.00M | 243.00M | 259.00M | 218.00M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 8.28B | 6.71B | 5.43B | 5.11B | 5.83B | 5.21B | 5.21B | 5.35B | 5.58B | 4.75B | 4.99B | 4.95B | 5.79B | 3.42B | 2.30B | 2.67B | 2.86B | 1.99B | 1.72B | 1.34B | 1.28B | 690.00M | 585.00M | 918.00M | 949.00M | 1.01B |
| EBITDA | 18.29B | 14.73B | 17.13B | 15.24B | 15.01B | 14.14B | 13.90B | 13.19B | 14.36B | 17.66B | 15.90B | 16.92B | 17.09B | 15.81B | 12.77B | 12.46B | 10.58B | 10.18B | 8.78B | 7.97B | 7.26B | 5.90B | 4.41B | 5.63B | 5.56B | 6.35B |
| EBITDA Ratio | 39.19% | 31.62% | 62.52% | 34.49% | 32.08% | 40.91% | 31.71% | 30.42% | 28.51% | 33.05% | 27.89% | 29.40% | 29.20% | 30.67% | 28.18% | 28.96% | 26.75% | 28.62% | 28.21% | 29.63% | 29.21% | 25.50% | 22.82% | 24.68% | 25.46% | 27.58% |
| Operating Income | 9.77B | 9.20B | 26.95B | 10.15B | 9.09B | 8.17B | 8.63B | 8.27B | 8.98B | 11.09B | 10.91B | 11.51B | 11.00B | 11.53B | 9.98B | 8.96B | 6.78B | 7.95B | 6.91B | 6.54B | 5.89B | 5.63B | 4.39B | 4.81B | 4.62B | 5.35B |
| Operating Income Ratio | 20.94% | 17.75% | 50.96% | 20.35% | 18.67% | 15.37% | 17.21% | 16.72% | 17.82% | 20.68% | 18.54% | 20.00% | 18.52% | 22.35% | 22.13% | 21.05% | 17.41% | 21.63% | 21.23% | 23.15% | 23.68% | 24.34% | 22.72% | 22.01% | 22.62% | 23.20% |
| Total Other Income/Expenses | -646.00M | 425.00M | -16.15B | -274.00M | -146.00M | -746.00M | -811.00M | -451.00M | -843.00M | 1.18B | -176.00M | -271.00M | -225.00M | 176.00M | -60.00M | 94.00M | 294.00M | -219.00M | 360.00M | -129.00M | -155.00M | 64.00M | 367.00M | 789.00M | 714.00M | 408.43M |
| Income Before Tax | 9.12B | 8.37B | 26.14B | 9.88B | 8.94B | 13.84B | 9.00B | 7.82B | 8.13B | 12.27B | 10.74B | 11.24B | 10.77B | 11.70B | 9.92B | 9.50B | 7.49B | 8.30B | 7.27B | 6.91B | 6.07B | 6.29B | 5.11B | 5.51B | 5.34B | 5.79B |
| Income Before Tax Ratio | 19.55% | 16.15% | 49.43% | 19.80% | 18.37% | 26.02% | 17.95% | 15.81% | 16.14% | 22.88% | 18.25% | 19.53% | 18.14% | 22.70% | 22.00% | 22.31% | 19.22% | 22.59% | 22.34% | 24.46% | 24.40% | 27.17% | 26.42% | 25.22% | 26.16% | 25.14% |
| Income Tax Expense | 551.00M | 1.42B | 2.12B | 1.81B | 1.79B | 1.22B | 1.30B | 1.12B | 1.11B | 1.55B | 1.44B | 1.63B | 1.53B | 1.73B | 1.47B | 1.34B | 947.00M | 1.28B | 1.12B | 1.13B | 1.01B | 1.07B | 869.00M | 1.11B | 1.15B | 1.37B |
| Net Income | 14.85B | 6.96B | 24.02B | 8.07B | 7.15B | 12.61B | 7.70B | 6.71B | 17.78B | 10.21B | 9.18B | 9.51B | 9.11B | 9.79B | 8.40B | 8.20B | 11.95B | 7.18B | 6.13B | 5.77B | 5.02B | 5.22B | 4.24B | 4.40B | 4.19B | 4.41B |
| Net Income Ratio | 31.83% | 13.42% | 45.43% | 16.18% | 14.68% | 23.72% | 15.36% | 13.58% | 35.29% | 19.04% | 15.60% | 16.51% | 15.35% | 18.99% | 18.62% | 19.24% | 30.67% | 19.52% | 18.85% | 20.42% | 20.17% | 22.56% | 21.92% | 20.13% | 20.51% | 19.13% |
| EPS | 7.15 | 3.19 | 10.71 | 3.54 | 3.12 | 5.44 | 3.28 | 2.82 | 7.40 | 4.21 | 3.76 | 3.93 | 3.75 | 4.28 | 3.70 | 3.62 | 5.15 | 3.06 | 2.63 | 2.28 | 1.99 | 1.88 | 1.49 | 1.70 | 0.62 | 0.33 |
| EPS Diluted | 7.10 | 3.17 | 10.63 | 3.52 | 3.08 | 5.38 | 3.25 | 2.80 | 7.29 | 4.13 | 3.70 | 3.89 | 3.70 | 4.26 | 3.69 | 3.59 | 5.13 | 3.04 | 2.62 | 2.27 | 1.97 | 1.84 | 1.49 | 1.70 | 0.62 | 0.33 |
| Weighted Avg Shares Out | 2.08B | 2.18B | 2.24B | 2.28B | 2.29B | 2.32B | 2.35B | 2.38B | 2.40B | 2.43B | 2.44B | 2.42B | 2.38B | 2.29B | 2.27B | 2.27B | 2.32B | 2.35B | 2.33B | 2.36B | 2.38B | 2.52B | 2.57B | 2.63B | 2.62B | 2.74B |
| Weighted Avg Shares Out (Dil) | 2.09B | 2.20B | 2.26B | 2.30B | 2.32B | 2.34B | 2.37B | 2.40B | 2.44B | 2.47B | 2.48B | 2.44B | 2.41B | 2.30B | 2.28B | 2.28B | 2.33B | 2.36B | 2.34B | 2.37B | 2.41B | 2.57B | 2.58B | 2.63B | 2.62B | 2.74B |
5 Large Drug Stocks Likely to Outpace Q3 Earnings Estimates
Let us look at some big drug/biotech stocks, NVO, NVS, PFE, REGN and BIIB, which are poised to beat on third-quarter earnings.
Novartis Gets CHMP Recommendation for Kisqali in Broader Population
The Committee for Medicinal Products for Human Use adopted a positive opinion for NVS' Kisqali to help reduce the risk of recurrence in people with HR+/HER2- early breast cancer.
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment with Kisqali® (ribociclib) in combination with an aromatase inhibitor1...
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
Basel, October 18, 2024 – Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing authorization for Kisqali® (ribociclib) for the adjuvant treatment...
1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move
Novartis is taking a more calculated and strategic approach to its growth.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Novartis (NVS) Upgraded to Buy: Here's Why
Novartis (NVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2 Magnificent Dividend Stocks to Buy and Hold Forever
These companies have compelling track records.
Here's Why Novartis (NVS) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Swiss competition authority closes Novartis probe without consequences
Switzerland's COMCO competition commission terminated an investigation against Novartis into possibly using blocking patents, without consequences, it said on Thursday.
Source: https://incomestatements.info
Category: Stock Reports